| For: | Cernea S, Onișor D, Roiban AL, Benedek T, Rat N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World J Cardiol 2024; 16(10): 580-594 [PMID: 39492975 DOI: 10.4330/wjc.v16.i10.580] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v16/i10/580.htm |
| Number | Citing Articles |
| 1 |
Wei Wang, Charlie Cooper. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression. World Journal of Cardiology 2025; 17(1): 102467 doi: 10.4330/wjc.v17.i1.102467
|
| 2 |
Elena-Daniela Grigorescu, Bogdan-Mircea Mihai, Georgiana-Diana Cazac-Panaite, Adina-Bianca Foșălău, Alina Onofriescu, Mariana Floria, Cristina Gena Dascălu, Alexandr Ceasovschih, Laurențiu Șorodoc, Cristina-Mihaela Lăcătușu. Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients. Journal of Clinical Medicine 2025; 14(16) doi: 10.3390/jcm14165772
|
| 3 |
N Naderi, M fardesharifi, D Allahverdi, H Poustchi, Z Yari. Independent and Combined Association of Overweight and Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) with 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients with Type 2 Diabetes. Iranian Journal of Nutrition Sciences and Food Technology 2026; 21(1) doi: 10.66224/nsft.21.1.23
|
| 4 |
Simona Cernea, Danusia Onișor, Andrada Larisa Roiban. Alcohol intake and markers of liver health in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease. Acta Marisiensis - Seria Medica 2026; 72(1) doi: 10.2478/amma-2025-0060
|
| 5 |
Simona Cernea, Andrada Larisa Roiban, Danusia Onișor. Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease. Medicina 2025; 61(9) doi: 10.3390/medicina61091518
|
| 6 |
Emir Muzurović, Ksenija Zečević, Dimitri P Mikhailidis. Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease. Current Cardiology Reports 2026; 28(1) doi: 10.1007/s11886-026-02367-3
|
| 7 |
Simona Cernea, Danusia Onișor, Andrada Larisa Roiban. The impact of the Mediterranean diet on liver steatosis and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Acta Marisiensis - Seria Medica 2025; 71(3) doi: 10.2478/amma-2025-0030
|
| 8 |
Huihui Ren, Mengyuan Hu, Yongli Yan, Mengke Cheng, Chengru Yang, Gang Yuan, Tingting Du. Association of the metabolic dysfunction-associated steatotic liver disease with cardiovascular and kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. Diabetes Research and Clinical Practice 2025; 229 doi: 10.1016/j.diabres.2025.112927
|
| 9 |
Luca Colangeli, Ilaria Milani, Maria Eugenia Parrotta, Susanna Longo, Alessandro Nucera, Massimo Federici, Simonetta Palleschi, Barbara Rossi, Alessandro Mantovani, Saverio Muscoli, Frida Leonetti, Danila Capoccia, Paolo Sbraccia, Valeria Guglielmi. Abdominal Obesity, Hepatic Steatosis, Oxidative Stress and Diastolic Dysfunction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences 2026; 27(4) doi: 10.3390/ijms27041968
|
| 10 |
Jiayang Lin, Ruxin Chen, Junlin Huang, Yating Liu, Chensihan Huang, Yan Huang, Bingyan Xu, Yunqian Li, Xinyu He, Hongzhen Lv, Xueyun Wei, Peizhen Zhang, Dan Guo, Jinhua Zhang, Huijie Zhang. MASLD-related fibrosis, but not MASLD, is associated with left ventricular concentric hypertrophy in patients with type 2 diabetes. Journal of Endocrinological Investigation 2025; 48(12) doi: 10.1007/s40618-025-02682-6
|
| 11 |
Danusia Onișor, Andrada Larisa Roiban, Simona Cernea. Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Patients—The Relationship with Platelets Indicators. Medicina 2024; 60(12) doi: 10.3390/medicina60122091
|
| 12 |
Simona Cernea, Andrada Larisa Roiban, Danusia Onișor, Nora Rat. Epicardial Adipose Tissue and Liver Fibrosis in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Liver Disease. Reviews in Cardiovascular Medicine 2025; 26(8) doi: 10.31083/RCM39534
|
| 13 |
Panagiotis Theofilis, Konstantinos Tsioufis, Dimitris Tousoulis. Response to the Letter to the Editor: Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-glucose Cotransporter 2 Inhibitors. Current Vascular Pharmacology 2025; 23(4) doi: 10.2174/0115701611401801250512101055
|